

Breogan Rodríguez-Acevedo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2545263/publications.pdf>

Version: 2024-02-01

19
papers

581
citations

759233

12
h-index

839539

18
g-index

21
all docs

21
docs citations

21
times ranked

1044
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021, 28, 3384-3395.	3.3	111
2	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. <i>Brain</i> , 2018, 141, 1075-1084.	7.6	98
3	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. <i>Multiple Sclerosis Journal</i> , 2018, 24, 301-312.	3.0	79
4	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , 2016, 87, 1368-1374.	1.1	42
5	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1658-1669.	3.0	41
6	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021, 97, e1641-e1652.	1.1	35
7	Optic Nerve Topography in Multiple Sclerosis Diagnosis. <i>Neurology</i> , 2021, 96, e482-e490.	1.1	32
8	Lesion topographies in multiple sclerosis diagnosis. <i>Neurology</i> , 2017, 89, 2351-2356.	1.1	27
9	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. <i>Multiple Sclerosis Journal</i> , 2021, 27, 913-921.	3.0	20
10	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, e1143.	6.0	17
11	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. <i>European Journal of Neurology</i> , 2022, 29, 1075-1081.	3.3	16
12	Simultaneous CMV and <i>Listeria</i> infection following alemtuzumab treatment for multiple sclerosis. <i>Neurology</i> , 2019, 92, 296-298.	1.1	15
13	Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis. <i>Neurourology and Urodynamics</i> , 2020, 39, 762-770.	1.5	13
14	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1138-1145.	3.0	11
15	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2022, 269, 452-459.	3.6	10
16	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 950-957.	3.0	7
17	Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis. <i>Clinica Chimica Acta</i> , 2019, 488, 135-142.	1.1	3
18	Clinical commentary on "Two cases of anaphylactic shock by methylprednisolone in neuromyelitis optica". <i>Multiple Sclerosis Journal</i> , 2018, 24, 1516-1517.	3.0	0

#	ARTICLE	IF	CITATIONS
19	Leucoencefalopatía multifocal progresiva en la era de los nuevos tratamientos modificadores de la enfermedad para la esclerosis múltiple. Medicina Clínica, 2021, 156, 509-514.	0.6	0